{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T23:39:58Z","timestamp":1788910798515,"version":"build-2803163510"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T00:00:00Z","timestamp":1767312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T00:00:00Z","timestamp":1769990400000},"content-version":"vor","delay-in-days":31,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Tianjin Key Medical Discipline Construction Project","award":["TJYXZDXK-3-004A-2"],"award-info":[{"award-number":["TJYXZDXK-3-004A-2"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Retin Vitr"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The study aimed to investigate the changes of vascular endothelial growth factor (VEGF) and connective tissue growth factor (CTGF) concentrations in proliferative diabetic retinopathy (PDR) combined with vitreous hemorrhage (VH) patients after panretinal photocoagulation (PRP), and to explore the risk factors associated with the occurrence of VH.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This cross-sectional study included 46 eyes surgically treated with pars plana vitrectomy (PPV), divided into three groups: PRP group (18 eyes) \u2013 PDR combined with VH patients with previous PRP; no-PRP group (18 eyes) \u2013 PDR combined with VH patients without previous PRP; and control group (10 eyes) \u2013 PPV performed for idiopathic macular hole (IMH) without diabetes mellitus. Both PRP and no-PRP groups underwent surgery due to non-clearing VH. Vitreous samples were obtained during PPV, then VEGF and CTGF concentrations were determined by enzyme-linked immunosorbent assay (ELISA).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Intravitreal VEGF levels were significantly lower in the PRP group (1968.10[1423.96-2341.68] pg\/mL) than in the no-PRP group (2815.71[2440.70-3395.52] pg\/mL) (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.015), but CTGF levels showed no statistical difference. The CTGF\/VEGF ratio was significantly higher in the PRP group (0.27[0.13\u20130.34]) than in the no-PRP group (0.13[0.11\u20130.18]) (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.002). Multiple linear regression analysis revealed that PRP treatment was independently associated with lower VEGF levels (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001) and a higher CTGF\/VEGF ratio (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.004). A positive correlation was observed between vitreous VEGF and CTGF levels in the no-PRP group (\n                      <jats:italic>r<\/jats:italic>\n                      \u2009=\u20090.486,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.041), whereas no correlation was observed in the PRP group.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>PRP treatment was associated with an alteration in the relationship between VEGF and CTGF levels in PDR patients, characterized by an upregulation of the CTGF\/VEGF ratio and a pro-fibrotic shift. Traction from microfibrous vascular membranes and the vitreous may represent key mechanisms contributing to VH in PDR patients after PRP treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>Trial registration number ChiCTR2400088011. Date of registration July 23, 2024.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40942-025-00784-0","type":"journal-article","created":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T06:24:43Z","timestamp":1767421483000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Intravitreal vascular endothelial growth factor and connective tissue growth factor levels and risk factors associated with vitreous hemorrhage in proliferative diabetic retinopathy after pan-retinal laser photocoagulation: a cross-sectional study"],"prefix":"10.1186","volume":"12","author":[{"given":"Zechen","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang","family":"Shu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaorong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jindong","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,2]]},"reference":[{"key":"784_CR1","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/s41574-020-00451-4","volume":"17","author":"DA Antonetti","year":"2021","unstructured":"Antonetti DA, Silva PS, Stitt AW. Current Understanding of the molecular and cellular pathology of diabetic retinopathy. Nat Rev Endocrinol. 2021;17:195\u2013206. https:\/\/doi.org\/10.1038\/s41574-020-00451-4.","journal-title":"Nat Rev Endocrinol"},{"key":"784_CR2","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.76.9.550","author":"R Walshe","year":"1992","unstructured":"Walshe R, Esser P, Wiedemann P, Heimann K. Proliferative retinal diseases: myofibroblasts cause chronic vitreoretinal traction. Br J Ophthalmol. 1992;76(9):550\u20132. https:\/\/doi.org\/10.1136\/bjo.76.9.550. PMID: 1420061; PMCID: PMC504347."},{"key":"784_CR3","doi-asserted-by":"publisher","first-page":"e51351","DOI":"10.7759\/cureus.51351","volume":"15","author":"M Yadav","year":"2023","unstructured":"Yadav M, Grezenko H, Kanukollu VMR, Rehman A, Bokhari SFH, Reza T, et al. A systematic review of the neuroprotective effects of vascular endothelial growth factor (VEGF) in diabetic retinopathy and diabetic macular edema: unraveling the molecular mechanisms and clinical implications. Cureus. 2023;15:e51351. https:\/\/doi.org\/10.7759\/cureus.51351.","journal-title":"Cureus"},{"key":"784_CR4","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.18240\/ijo.2018.09.20","volume":"11","author":"T Ma","year":"2018","unstructured":"Ma T, Dong L-J, Du X-L, Niu R, Hu B-J. Research progress on the role of connective tissue growth factor in fibrosis of diabetic retinopathy. Int J Ophthalmol. 2018;11:1550\u20134. https:\/\/doi.org\/10.18240\/ijo.2018.09.20.","journal-title":"Int J Ophthalmol"},{"key":"784_CR5","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.exer.2014.10.016","volume":"133","author":"I Klaassen","year":"2015","unstructured":"Klaassen I, van Geest RJ, Kuiper EJ, van Noorden CJF, Schlingemann RO. The role of CTGF in diabetic retinopathy. Exp Eye Res. 2015;133:37\u201348. https:\/\/doi.org\/10.1016\/j.exer.2014.10.016.","journal-title":"Exp Eye Res"},{"key":"784_CR6","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1096\/fj.01-0332fje","volume":"16","author":"I Inoki","year":"2002","unstructured":"Inoki I, Shiomi T, Hashimoto G, Enomoto H, Nakamura H, Makino K, et al. Connective tissue growth factor binds vascular endothelial growth factor (VEGF) and inhibits VEGF-induced angiogenesis. FASEB J Off Publ Fed Am Soc Exp Biol. 2002;16:219\u201321. https:\/\/doi.org\/10.1096\/fj.01-0332fje.","journal-title":"FASEB J Off Publ Fed Am Soc Exp Biol"},{"key":"784_CR7","doi-asserted-by":"publisher","first-page":"4267","DOI":"10.1167\/iovs.06-0804","volume":"48","author":"EJ Kuiper","year":"2007","unstructured":"Kuiper EJ, Hughes JM, Van Geest RJ, Vogels IMC, Goldschmeding R, Van Noorden CJF, et al. Effect of VEGF-A on expression of profibrotic growth factor and extracellular matrix genes in the retina. Invest Ophthalmol Vis Sci. 2007;48:4267\u201376. https:\/\/doi.org\/10.1167\/iovs.06-0804.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"784_CR8","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1136\/bjophthalmol-2011-301005","volume":"96","author":"RJ Van Geest","year":"2012","unstructured":"Van Geest RJ, Lesnik-Oberstein SY, Tan HS, Mura M, Goldschmeding R, Van Noorden CJF, et al. A shift in the balance of vascular endothelial growth factor and connective tissue growth factor by bevacizumab causes the angiofibrotic switch in proliferative diabetic retinopathy. Br J Ophthalmol. 2012;96:587\u201390. https:\/\/doi.org\/10.1136\/bjophthalmol-2011-301005.","journal-title":"Br J Ophthalmol"},{"key":"784_CR9","doi-asserted-by":"publisher","first-page":"e2675","DOI":"10.1371\/journal.pone.0002675","volume":"3","author":"EJ Kuiper","year":"2008","unstructured":"Kuiper EJ, Van Nieuwenhoven FA, de Smet MD, van Meurs JC, Tanck MW, Oliver N, et al. The angio-fibrotic switch of VEGF and CTGF in proliferative diabetic retinopathy. PLoS ONE. 2008;3:e2675. https:\/\/doi.org\/10.1371\/journal.pone.0002675.","journal-title":"PLoS ONE"},{"key":"784_CR10","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1001\/archopht.124.10.1457","volume":"124","author":"EJ Kuiper","year":"2006","unstructured":"Kuiper EJ. Association of connective tissue growth factor with fibrosis in vitreoretinal disorders in the human eye. Arch Ophthalmol. 2006;124:1457. https:\/\/doi.org\/10.1001\/archopht.124.10.1457.","journal-title":"Arch Ophthalmol"},{"key":"784_CR11","doi-asserted-by":"publisher","first-page":"758","DOI":"10.2337\/diacare.27.3.758","volume":"27","author":"DR Hinton","year":"2004","unstructured":"Hinton DR, Spee C, He S, Weitz S, Usinger W, LaBree L, et al. Accumulation of NH2-terminal fragment of connective tissue growth factor in the vitreous of patients with proliferative diabetic retinopathy. Diabetes Care. 2004;27:758\u201364. https:\/\/doi.org\/10.2337\/diacare.27.3.758.","journal-title":"Diabetes Care"},{"key":"784_CR12","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1369\/jhc.7A7258.2007","volume":"55","author":"EJ Kuiper","year":"2007","unstructured":"Kuiper EJ, Roestenberg P, Ehlken C, Lambert V, van Treslong-de Groot HB, Lyons KM, et al. Angiogenesis is not impaired in connective tissue growth factor (CTGF) knock-out mice. J Histochem Cytochem Off J Histochem Soc. 2007;55:1139\u201347. https:\/\/doi.org\/10.1369\/jhc.7A7258.2007.","journal-title":"J Histochem Cytochem Off J Histochem Soc"},{"key":"784_CR13","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s11892-021-01403-6","volume":"21","author":"LA Everett","year":"2021","unstructured":"Everett LA, Paulus YM. Laser therapy in the treatment of diabetic retinopathy and diabetic macular edema. Curr Diab Rep. 2021;21:35. https:\/\/doi.org\/10.1007\/s11892-021-01403-6.","journal-title":"Curr Diab Rep"},{"key":"784_CR14","doi-asserted-by":"publisher","first-page":"265","DOI":"10.22336\/rjo.2022.49","volume":"66","author":"F Ni\u0161i\u0107","year":"2022","unstructured":"Ni\u0161i\u0107 F, Pidro A, Lepara O, Fajki\u0107 A, Miokovi\u0107 AP, Sulji\u0107 E, et al. Effect of pan-retinal laser photocoagulation on intravitreal vascular endothelial growth factor concentration in proliferative diabetic retinopathy. Romanian J Ophthalmol. 2022;66:265\u201370. https:\/\/doi.org\/10.22336\/rjo.2022.49.","journal-title":"Romanian J Ophthalmol"},{"key":"784_CR15","unstructured":"Long-term visual outcome in proliferative diabetic retinopathy patients after panretinal photocoagulation [Internet]. PubMed. [cited 2024 Aug 28]. https:\/\/pubmed.ncbi.nlm.nih.gov\/10413257\/."},{"key":"784_CR16","unstructured":"Zhu H. Expression of vitreous cytokines in patients with proliferative diabetic retinopathy exhibiting different fundus manifestations [D]. Qingdao University, 2017 (in Chinese)."},{"key":"784_CR17","doi-asserted-by":"publisher","first-page":"e29","DOI":"10.1111\/aos.14189","volume":"98","author":"SY Moon","year":"2020","unstructured":"Moon SY, Park SP, Kim Y-K. Evaluation of posterior vitreous detachment using ultrasonography and optical coherence tomography. Acta Ophthalmol (Copenh). 2020;98:e29\u201335. https:\/\/doi.org\/10.1111\/aos.14189.","journal-title":"Acta Ophthalmol (Copenh)"},{"key":"784_CR18","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.phrs.2015.05.013","volume":"99","author":"T Behl","year":"2015","unstructured":"Behl T, Kotwani A. Exploring the various aspects of the pathological role of vascular endothelial growth factor (VEGF) in diabetic retinopathy. Pharmacol Res. 2015;99:137\u201348. https:\/\/doi.org\/10.1016\/j.phrs.2015.05.013.","journal-title":"Pharmacol Res"},{"key":"784_CR19","doi-asserted-by":"publisher","first-page":"1897344","DOI":"10.1155\/2022\/1897344","volume":"2022","author":"J-W Kwon","year":"2022","unstructured":"Kwon J-W, Oh J. Aqueous humor analyses in patients with diabetic retinopathy who had undergone panretinal photocoagulation. J Diabetes Res. 2022;2022:1897344. https:\/\/doi.org\/10.1155\/2022\/1897344.","journal-title":"J Diabetes Res"},{"key":"784_CR20","doi-asserted-by":"publisher","first-page":"727407","DOI":"10.3389\/fmed.2021.727407","volume":"8","author":"G Wu","year":"2021","unstructured":"Wu G, Liu B, Wu Q, Tang C, Du Z, Fang Y, et al. Correlations between different angiogenic and inflammatory factors in vitreous fluid of eyes with proliferative diabetic retinopathy. Front Med. 2021;8:727407. https:\/\/doi.org\/10.3389\/fmed.2021.727407.","journal-title":"Front Med"},{"key":"784_CR21","doi-asserted-by":"publisher","first-page":"493043","DOI":"10.1155\/2012\/493043","volume":"2012","author":"AM Abu El-Asrar","year":"2012","unstructured":"Abu El-Asrar AM, Imtiaz Nawaz M, Kangave D, Siddiquei MM, Geboes K. Osteopontin and other regulators of angiogenesis and fibrogenesis in the vitreous from patients with proliferative vitreoretinal disorders. Mediators Inflamm. 2012;2012:493043. https:\/\/doi.org\/10.1155\/2012\/493043.","journal-title":"Mediators Inflamm"},{"key":"784_CR22","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s10792-007-9053-x","volume":"27","author":"AM Abu El-Asrar","year":"2007","unstructured":"Abu El-Asrar AM, Van den Steen PE, Al-Amro SA, Missotten L, Opdenakker G, Geboes K. Expression of angiogenic and fibrogenic factors in proliferative vitreoretinal disorders. Int Ophthalmol. 2007;27:11\u201322. https:\/\/doi.org\/10.1007\/s10792-007-9053-x.","journal-title":"Int Ophthalmol"},{"key":"784_CR23","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.exer.2015.04.004","volume":"142","author":"S Roy","year":"2016","unstructured":"Roy S, Amin S, Roy S. Retinal fibrosis in diabetic retinopathy. Exp Eye Res. 2016;142:71\u20135. https:\/\/doi.org\/10.1016\/j.exer.2015.04.004.","journal-title":"Exp Eye Res"},{"key":"784_CR24","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1186\/s12886-021-01964-w","volume":"21","author":"HE Feng","year":"2021","unstructured":"Feng HE, Weihong YU, Dong F. Observation of retinal neovascularization using optical coherence tomography angiography after panretinal photocoagulation for proliferative diabetic retinopathy. BMC Ophthalmol. 2021;21:252. https:\/\/doi.org\/10.1186\/s12886-021-01964-w.","journal-title":"BMC Ophthalmol"},{"key":"784_CR25","doi-asserted-by":"publisher","first-page":"471","DOI":"10.2147\/OPTH.S400474","volume":"17","author":"V Patel","year":"2023","unstructured":"Patel V, Rohowetz LJ, Pakravan P, Kalavar M, Yannuzzi NA, Sridhar J. Outcomes of Pars plana vitrectomy with panretinal photocoagulation for treatment of proliferative diabetic retinopathy without retinal detachment: A Seven-Year retrospective study. Clin Ophthalmol Auckl NZ. 2023;17:471\u20138. https:\/\/doi.org\/10.2147\/OPTH.S400474.","journal-title":"Clin Ophthalmol Auckl NZ"},{"key":"784_CR26","doi-asserted-by":"publisher","first-page":"138","DOI":"10.3269\/1970-5492.2020.15.34","volume":"15","author":"B Gaonkar","year":"2020","unstructured":"Gaonkar B, Prabhu K, Rao P, Kamat A, Rao K, Varma M. Plasma levels of angiogenic and angiostatic factors after panretinal photocoagulation for proliferative diabetic retinopathy. EuroMediterranean Biomed J EuroMediterranean Biomedical J. 2020;15:138\u201341. https:\/\/doi.org\/10.3269\/1970-5492.2020.15.34.","journal-title":"EuroMediterranean Biomed J EuroMediterranean Biomedical J"},{"key":"784_CR27","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1016\/s0002-9394(14)74789-0","volume":"113","author":"DR Guyer","year":"1992","unstructured":"Guyer DR, D\u2019Amico DJ, Smith CW. Subretinal fibrosis after laser photocoagulation for diabetic macular edema. Am J Ophthalmol. 1992;113:652\u20136. https:\/\/doi.org\/10.1016\/s0002-9394(14)74789-0.","journal-title":"Am J Ophthalmol"},{"key":"784_CR28","doi-asserted-by":"publisher","first-page":"8701","DOI":"10.1167\/iovs.11-7870","volume":"52","author":"L Pi","year":"2011","unstructured":"Pi L, Xia H, Liu J, Shenoy AK, Hauswirth WW, Scott EW. Role of connective tissue growth factor in the retinal vasculature during development and ischemia. Invest Ophthalmol Vis Sci. 2011;52:8701\u201310. https:\/\/doi.org\/10.1167\/iovs.11-7870.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"784_CR29","doi-asserted-by":"publisher","unstructured":"Zhao Q, An W, Han J. Cytokine levels in the aqueous humor of young and senior patients with proliferative diabetic retinopathy. Eur J Ophthalmol. 2022;11206721221129431. https:\/\/doi.org\/10.1177\/11206721221129431.","DOI":"10.1177\/11206721221129431"},{"key":"784_CR30","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1631\/jzus.B1400024","volume":"15","author":"B Ruszkowska-Ciastek","year":"2014","unstructured":"Ruszkowska-Ciastek B, Sokup A, Socha MW, Ruprecht Z, Ha\u0142as L, G\u00f3ralczyk B, et al. A preliminary evaluation of VEGF-A, VEGFR1 and VEGFR2 in patients with well-controlled type 2 diabetes mellitus. J Zhejiang Univ Sci B. 2014;15:575\u201381. https:\/\/doi.org\/10.1631\/jzus.B1400024.","journal-title":"J Zhejiang Univ Sci B"},{"key":"784_CR31","doi-asserted-by":"publisher","first-page":"e726","DOI":"10.1111\/aos.14957","volume":"100","author":"Z Hu","year":"2022","unstructured":"Hu Z, Cao X, Chen L, Su Y, Ji J, Yuan S, et al. Monitoring intraocular proangiogenic and profibrotic cytokines within 7 days after adjunctive anti-vascular endothelial growth factor therapy for proliferative diabetic retinopathy. Acta Ophthalmol (Copenh). 2022;100:e726\u201336. https:\/\/doi.org\/10.1111\/aos.14957.","journal-title":"Acta Ophthalmol (Copenh)"},{"key":"784_CR32","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.18240\/ijo.2024.10.07","volume":"17","author":"H-S Li","year":"2024","unstructured":"Li H-S, Lyu X, Rong A, Bi Y-L, Xu W, Cui H-P. Vascular endothelial growth factor\/connective tissue growth factor and proteomic analysis of aqueous humor after intravitreal conbercept for proliferative diabetes retinopathy. Int J Ophthalmol. 2024;17:1816\u201327. https:\/\/doi.org\/10.18240\/ijo.2024.10.07.","journal-title":"Int J Ophthalmol"},{"key":"784_CR33","doi-asserted-by":"publisher","first-page":"332","DOI":"10.3892\/etm.2021.9763","volume":"21","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Gao Z, Zhang X, Yuan Z, Ma T, Li G, et al. Effect of intravitreal conbercept injection on VEGF-A and -B levels in the aqueous and vitreous humor of patients with proliferative diabetic retinopathy. Exp Ther Med. 2021;21:332. https:\/\/doi.org\/10.3892\/etm.2021.9763.","journal-title":"Exp Ther Med"},{"key":"784_CR34","doi-asserted-by":"publisher","first-page":"5677","DOI":"10.1167\/iovs.07-0156","volume":"48","author":"M Itaya","year":"2007","unstructured":"Itaya M, Sakurai E, Nozaki M, Yamada K, Yamasaki S, Asai K, et al. Upregulation of VEGF in murine retina via monocyte recruitment after retinal scatter laser photocoagulation. Invest Ophthalmol Vis Sci. 2007;48:5677\u201383. https:\/\/doi.org\/10.1167\/iovs.07-0156.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"784_CR35","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s004170000235","volume":"239","author":"N Ogata","year":"2001","unstructured":"Ogata N, Ando A, Uyama M, Matsumura M. Expression of cytokines and transcription factors in photocoagulated human retinal pigment epithelial cells. Graefes Arch Clin Exp Ophthalmol Albrecht Von Graefes Arch Klin Exp Ophthalmol. 2001;239:87\u201395. https:\/\/doi.org\/10.1007\/s004170000235.","journal-title":"Graefes Arch Clin Exp Ophthalmol Albrecht Von Graefes Arch Klin Exp Ophthalmol"},{"key":"784_CR36","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/s13098-022-00892-z","volume":"14","author":"J Li","year":"2022","unstructured":"Li J, Li X, Lei M, Li W, Chen W, Ma T, et al. A prediction model for worsening diabetic retinopathy after panretinal photocoagulation. Diabetol Metab Syndr. 2022;14:124. https:\/\/doi.org\/10.1186\/s13098-022-00892-z.","journal-title":"Diabetol Metab Syndr"},{"key":"784_CR37","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s10792-007-9106-1","volume":"28","author":"G Kleinmann","year":"2008","unstructured":"Kleinmann G, Hauser D, Schechtman E, Landa G, Bukelman A, Pollack A. Vitreous hemorrhage in diabetic eyes previously treated with panretinal photocoagulation. Int Ophthalmol. 2008;28:29\u201334. https:\/\/doi.org\/10.1007\/s10792-007-9106-1.","journal-title":"Int Ophthalmol"},{"key":"784_CR38","doi-asserted-by":"publisher","first-page":"14484","DOI":"10.1038\/s41598-022-17214-y","volume":"12","author":"JW Lim","year":"2022","unstructured":"Lim JW, Lee SJ, Sung JY, Kim J-S, Nam KY. Effect of prophylactic anti-VEGF injections on the prevention of recurrent vitreous hemorrhage in PDR patients after PRP. Sci Rep. 2022;12:14484. https:\/\/doi.org\/10.1038\/s41598-022-17214-y.","journal-title":"Sci Rep"},{"key":"784_CR39","doi-asserted-by":"publisher","first-page":"2989","DOI":"10.3390\/jcm12082989","volume":"12","author":"M Baget-Bernaldiz","year":"2023","unstructured":"Baget-Bernaldiz M, Romero-Aroca P, Mira-Puerto A, Bautista-Perez A, Roca-Borrut I, Vizcarro M, et al. Risk factors for recurrent vitreous hemorrhage in type 2 diabetes mellitus patients after posterior vitrectomy. J Clin Med. 2023;12:2989. https:\/\/doi.org\/10.3390\/jcm12082989.","journal-title":"J Clin Med"},{"key":"784_CR40","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.ajo.2009.11.022","volume":"149","author":"MW Johnson","year":"2010","unstructured":"Johnson MW. Posterior vitreous detachment: evolution and complications of its early stages. Am J Ophthalmol. 2010;149:371\u201382.e1. https:\/\/doi.org\/10.1016\/j.ajo.2009.11.022.","journal-title":"Am J Ophthalmol"},{"key":"784_CR41","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1136\/bjo.81.7.527","volume":"81","author":"A Kakehashi","year":"1997","unstructured":"Kakehashi A, Kado M, Akiba J, Hirokawa H. Variations of posterior vitreous detachment. Br J Ophthalmol. 1997;81:527\u201332. https:\/\/doi.org\/10.1136\/bjo.81.7.527.","journal-title":"Br J Ophthalmol"},{"key":"784_CR42","doi-asserted-by":"publisher","first-page":"2611","DOI":"10.1016\/j.ophtha.2013.07.042","volume":"120","author":"JS Duker","year":"2013","unstructured":"Duker JS, Kaiser PK, Binder S, de Smet MD, Gaudric A, Reichel E, et al. The international vitreomacular traction study group classification of vitreomacular adhesion, traction, and macular hole. Ophthalmology. 2013;120:2611\u20139. https:\/\/doi.org\/10.1016\/j.ophtha.2013.07.042.","journal-title":"Ophthalmology"},{"key":"784_CR43","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1111\/aos.16755","volume":"102","author":"KA van Overdam","year":"2024","unstructured":"van Overdam KA, Veckeneer M, Kili\u00e7 E, van Etten PG, Sebag J, van Meurs JC. Vitreoschisis-induced vitreous cortex remnants in proliferative vitreoretinopathy: A comprehensive review from basic research to clinical practice. Acta Ophthalmol (Copenh). 2024;102:859\u201380. https:\/\/doi.org\/10.1111\/aos.16755.","journal-title":"Acta Ophthalmol (Copenh)"}],"container-title":["International Journal of Retina and Vitreous"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40942-025-00784-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40942-025-00784-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40942-025-00784-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T16:01:51Z","timestamp":1781625711000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40942-025-00784-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,2]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["784"],"URL":"https:\/\/doi.org\/10.1186\/s40942-025-00784-0","relation":{"references":[{"id-type":"doi","id":"10.1136\/bjo.76.9.550","asserted-by":"subject"}]},"ISSN":["2056-9920"],"issn-type":[{"value":"2056-9920","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,2]]},"assertion":[{"value":"22 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study protocol was reviewed and approved by the Ethics Committee of Tianjin Medical University Eye Hospital, approval number 2024KY-36. All procedures were carried in accordance with the tenets of the Declaration of Helsinki. Informed consent was obtained from all participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"19"}}